CervoMed sees cash runway into mid-2026

As of December 31, 2024, CervoMed (CRVO) had approximately $38.9 million in cash, cash equivalents and marketable securities, as compared to $7.8 million as of December 31, 2023. The increase in cash on-hand compared to 2023 was primarily attributable to the upfront proceeds received in CervoMed’s private placement completed in April 2024. Based on its current operating plan, CervoMed believes its cash, cash equivalents and marketable securities on hand as of December 31, 2024, will enable the Company to fund its planned operating expenses and capital expenditure requirements into mid-2026.